Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer

Por Chen, Xiaoying, Li, Cheryl, Ewesuedo, Reginald, Yin, Donghua
Publicado no Cancer Chemother Pharmacol (2019)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cance...

Por Chen, Xiaoying, Li, Cheryl, Ewesuedo, Reginald, Yin, Donghua
Publicado no Cancer Chemother Pharmacol (2019)

Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents

Por Elmeliegy, Mohamed, Udata, Chandrasekhar, Liao, Ken, Yin, Donghua
Publicado no Clin Pharmacokinet (2021)

A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing

Por Liao, Kai H., Udata, Chandrasekhar, Yin, Donghua, Sewell, K. Lea, Kantaridis, Constantino, Alvarez, Daniel F., Meng, Xu
Publicado no Br J Clin Pharmacol (2020)

Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators

Por Marhefka, Craig A., Gao, Wenqing, Chung, Kiwon, Kim, Juhyun, He, Yali, Yin, Donghua, Bohl, Casey, Dalton, James T., Miller, Duane D.
Publicado em 2004

Evaluating imbalances of adverse events during biosimilar development

Por Vana, Alicia M., Freyman, Amy W., Reich, Steven D., Yin, Donghua, Li, Ruifeng, Anderson, Scott, Jacobs, Ira A., Zacharchuk, Charles M., Ewesuedo, Reginald
Publicado no MAbs (2016)

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Por Haluska, Paul, Worden, Frank, Olmos, David, Yin, Donghua, Schteingart, David, Batzel, Gretchen N., Luisa Paccagnella, M., de Bono, Johann S., Gualberto, Antonio, Hammer, Gary D.
Publicado em 2009

Time trend of cardiometabolic risk factors over a 10-year period in the office-working population in China

Por Cheng, Yang, Yin, Hongli, Zheng, Hui, Yin, Donghua, Yin, Gang, Ying, Shanping, Li, Xiaohong, Dai, Hui, Zhao, Lvkun, Shen, Chong, Shen, Zhixiang, Gu, Liubao
Publicado no BMJ Open (2019)

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)(1)

Por Yin, Donghua, Barker, Kerry B, Li, Ruifeng, Meng, Xu, Reich, Steven D, Ricart, Alejandro D, Rudin, Dan, Taylor, Carrie T, Zacharchuk, Charles M, Hansson, Arne G
Publicado no Br J Clin Pharmacol (2014)

A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

Por Cohen, Stanley, Emery, Paul, Greenwald, Maria, Yin, Donghua, Becker, Jean‐Claude, Melia, Lisa Ann, Li, Ruifeng, Gumbiner, Barry, Thomas, Dolca, Spencer‐Green, George, Meng, Xu
Publicado no Br J Clin Pharmacol (2016)

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

Por Juergens, Heribert, Daw, Najat C., Geoerger, Birgit, Ferrari, Stefano, Villarroel, Milena, Aerts, Isabelle, Whelan, Jeremy, Dirksen, Uta, Hixon, Mary L., Yin, Donghua, Wang, Tao, Green, Stephanie, Paccagnella, Luisa, Gualberto, Antonio
Publicado em 2011

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

Por Williams, Jason H., Hutmacher, Matthew M., Zierhut, Matthew L., Becker, Jean‐Claude, Gumbiner, Barry, Spencer‐Green, George, Melia, Lisa A., Liao, Kai‐Hsin, Suster, Matthew, Yin, Donghua, Li, Ruifeng, Meng, Xu
Publicado no Br J Clin Pharmacol (2016)

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort stu...

Por Olmos, David, Postel-Vinay, Sophie, Molife, L Rhoda, Okuno, Scott H, Schuetze, Scott M, Paccagnella, M Luisa, Batzel, Gretchen N, Yin, Donghua, Pritchard-Jones, Kathryn, Judson, Ian, Worden, Francis P, Gualberto, Antonio, Scurr, Michelle, de Bono, Johann S, Haluska, Paul
Publicado em 2009

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

Por Karp, Daniel D., Pollak, Michael N., Cohen, Roger B., Eisenberg, Peter D., Haluska, Paul, Yin, Donghua, Lipton, Allan, Demers, Laurence, Leitzel, Kim, Hixon, Mary L., Terstappen, Leon W., Garland, Linda, Paz-Ares, Luis G., Cardenal, Felipe, Langer, Corey J., Gualberto, Antonio
Publicado em 2009

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind st...

Por Pegram, Mark D., Bondarenko, Igor, Zorzetto, Marina Moreira Costa, Hingmire, Sachin, Iwase, Hirotaka, Krivorotko, Petr V., Lee, Keun Seok, Li, Rubi K., Pikiel, Joanna, Aggarwal, Rajesh, Ewesuedo, Reginald, Freyman, Amy, Li, Ray, Vana, Alicia, Yin, Donghua, Zacharchuk, Charles, Tan-Chiu, Elizabeth
Publicado no Br J Cancer (2018)

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of meta...

Por Noel, Marcus, O’Reilly, Eileen M., Wolpin, Brian M., Ryan, David P., Bullock, Andrea J., Britten, Carolyn D., Linehan, David C., Belt, Brian A., Gamelin, Eric C., Ganguly, Bishu, Yin, Donghua, Joh, Tenshang, Jacobs, Ira A., Taylor, Carrie T., Lowery, Maeve A.
Publicado no Invest New Drugs (2019)